Navigating key news stories in pharma

Sanner Banner

Featured Stories

Featured
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability
Future Biopharma
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability
Future Biopharma

Ahead of CPHI Milan, Event Director Tara Dougal shares insights on the key themes, new dedicated zones, and networking opportunities shaping this year’s global biopharmaceutical gathering.

Read more →
Future Biopharma
News
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability
Future Biopharma
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability
Future Biopharma

Ahead of CPHI Milan, Event Director Tara Dougal shares insights on the key themes, new dedicated zones, and networking opportunities shaping this year’s global biopharmaceutical gathering.

Read more →
Future Biopharma
CPHI Milan 2026: Balancing Viscosity, Compliance, and Sustainability in Fill/Finish
Future Biopharma
CPHI Milan 2026: Balancing Viscosity, Compliance, and Sustainability in Fill/Finish
Future Biopharma

Ahead of CPHI Milan 2026, Professor Hanns-Christian Mahler from ten23 health, explores how expanding dose volumes, flexible CDMO partnerships, and steadfast sustainability commitments are reshaping modern bioprocessing.

Read more →
Future Biopharma
CPHI Milan 2026: Overcoming Formulation Barriers in LAIs
Future Biopharma
CPHI Milan 2026: Overcoming Formulation Barriers in LAIs
Future Biopharma

As demand for patient-centric chronic disease treatments grows, Nanexa CTO Mårten Rooth discusses how atomic layer deposition enables high drug loads and controlled release in long-acting injectables.

Read more →
Future Biopharma

R&D

Featured
Nanoform Highlights CESS Benefits Versus Spray-Dried ASDs
Nanoform Highlights CESS Benefits Versus Spray-Dried ASDs

According to the company, its commercial-scale nanoparticle manufacturing technology could reduce production costs and solvent use while increasing drug loading.

Read more →
Moonwalk Biosciences Closes Oversubscribed Series B Financing Round
Moonwalk Biosciences Closes Oversubscribed Series B Financing Round

The company has managed to raise USD 70 million, which it will use to progress its lead candidate into first-in-human clinical trials and broaden its pipeline of siRNA medicines.

Read more →
MedPharm Gains Olink Certification to Introduce Proteomic Analysis Services
MedPharm Gains Olink Certification to Introduce Proteomic Analysis Services

Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis alongside its human-relevant disease models.

Read more →
EyePoint Positions DURAVYU as a Potential Treatment for Wet AMD
EyePoint Positions DURAVYU as a Potential Treatment for Wet AMD

Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden, with most patients requiring zero or one supplemental injection through Week 56.

Read more →

Expansion

Featured
Circio Raises Funds to Advance in vivo CAR-T Program
Circio Raises Funds to Advance in vivo CAR-T Program

The Norwegian biotech plans to use the raised capital to expand its circular RNA platform and secure complementary vector and delivery technologies for an in vivo CAR-T therapy.

Read more →
Northway Biotech Expands CGMP Cell-Based Manufacturing
Northway Biotech Expands CGMP Cell-Based Manufacturing

The Lithuanian CDMO has opened a new facility in Vilnius that can support advanced and personalized therapies, including cell-based applications, therapeutic vaccines, and 3D human tissue technologies.

Read more →
Codis Expands European Footprint with Catalent Nottingham Facility Acquisition
Codis Expands European Footprint with Catalent Nottingham Facility Acquisition

By combining Nottingham’s development capabilities with its expanded Haverhill site, Codis creates an integrated UK pathway spanning early-stage development to commercial-scale supply.

Read more →
Cyllene Therapeutics Successfully Raises Millions to Advance Genetic Medicine Candidate
Cyllene Therapeutics Successfully Raises Millions to Advance Genetic Medicine Candidate

The biotech, which was formerly known as EG 427, will use the funds raised in its Series C financing round to advance its lead precision genetic medicine candidate, EG110A.

Read more →

Dealmaking

Featured
Novo Nordisk Secures Global License to Nanexa’s ALD Drug Delivery Platform
Novo Nordisk Secures Global License to Nanexa’s ALD Drug Delivery Platform

A global licensing agreement worth up to EUR 1.165 billion will leverage Nanexa's PharmaShell technology to develop long-acting injectable treatments for obesity and cardiometabolic conditions.

Read more →
Lifecore Biomedical Signs Major Commercial Site-Transfer Deal
Lifecore Biomedical Signs Major Commercial Site-Transfer Deal

The Minnesota injectables CDMO has signed a technical transfer and manufacturing agreement for a currently marketed, high-viscosity injectable, marking its seventh late‑stage commercial program and 11th pipeline addition in 2026.

Read more →
Lilly to Acquire Merida Biosciences for Antibody-Degradation Technology
Lilly to Acquire Merida Biosciences for Antibody-Degradation Technology

Through this acquisition, Eli Lilly will strengthen its immunology capabilities by gaining access to a first-in-class antibody-degradation platform that has been designed to remove disease-causing antibodies.

Read more →
Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals
Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals

After closing an all-stock merger with complement specialist Kira Pharmaceuticals, Jasper Therapeutics is set to create a diversified immunology company.

Read more →

Strategy

Featured
Codis Appoints Steven Facer in New Role as Chief Commercial Officer
Codis Appoints Steven Facer in New Role as Chief Commercial Officer

The newly created role will bring the CDMO’s sales, marketing, and business development teams under a unified commercial strategy across the U.S. and UK.

Read more →
Building a Value-Driven Platform
Building a Value-Driven Platform

SPONSORED CONTENT: As the biopharmaceutical landscape increasingly demands integrated technical operations, GCCs are expanding beyond back-office efficiency, reveals Shashidhar K L from Pivot Path.

Read more →
Closing the Bioprocessing Gap
Closing the Bioprocessing Gap

As the divide between upstream output and downstream capability in bioprocessing expands, it is becoming necessary for the biopharma industry to address plant capacity, process intensification, digital connectivity, and business feasibility.

Read more →
Overcoming the Hurdles to Oral Peptide Development
Overcoming the Hurdles to Oral Peptide Development

Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical workflows designed to bring oral peptides to market safely and predictably.

Read more →

Future Biopharma

Featured
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability

Ahead of CPHI Milan, Event Director Tara Dougal shares insights on the key themes, new dedicated zones, and networking opportunities shaping this year’s global biopharmaceutical gathering.

Read more →
CPHI Milan 2026: Balancing Viscosity, Compliance, and Sustainability in Fill/Finish
CPHI Milan 2026: Balancing Viscosity, Compliance, and Sustainability in Fill/Finish

Ahead of CPHI Milan 2026, Professor Hanns-Christian Mahler from ten23 health, explores how expanding dose volumes, flexible CDMO partnerships, and steadfast sustainability commitments are reshaping modern bioprocessing.

Read more →
CPHI Milan 2026: Overcoming Formulation Barriers in LAIs
CPHI Milan 2026: Overcoming Formulation Barriers in LAIs

As demand for patient-centric chronic disease treatments grows, Nanexa CTO Mårten Rooth discusses how atomic layer deposition enables high drug loads and controlled release in long-acting injectables.

Read more →
Deciphering the AMT Designation Program
Deciphering the AMT Designation Program

As biopharma moves beyond traditional batch processing, industry leaders evaluate how the FDA’s Advanced Manufacturing Technology designation program is reshaping process innovation, risk mitigation, and strategic CDMO partnerships.

Read more →

Regulatory

Featured
Roche Gets Nod from European Commission for Susvimo
Roche Gets Nod from European Commission for Susvimo

The European Commission has approved the ranibizumab 100 mg/mL injectable solution (Susvimo) from Roche as a treatment of neovascular age-related macular degeneration.

Read more →
Camizestrant Combination for Metastatic Breast Cancer Gains FDA Approval
Camizestrant Combination for Metastatic Breast Cancer Gains FDA Approval

The U.S. regulatory body has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors, to treat adults with HR‑positive, HER2‑negative metastatic breast cancer who are resistant to standard endocrine therapy.

Read more →
Weekly HIV Pill Advances Toward Regulatory Submission
Weekly HIV Pill Advances Toward Regulatory Submission

A combination therapy from Gilead and Merck has met its clinical efficacy endpoint, demonstrating non-inferiority to existing daily treatments with no new safety concerns identified in treatment-experienced patient population.

Read more →
FDA Extends Review of AstraZeneca’s Camizestran
FDA Extends Review of AstraZeneca’s Camizestran

AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer evidence that early intervention improves long-term outcomes for patients with advanced breast cancer.

Read more →

Upcoming Events

Summary Block
This block has no content yet. Items you add to the page connected to this block will display here.
Featured